Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
LAVA Therapeutics N.V. is a clinical-stage immuno-oncology company developing Gammabody bispecific antibodies that engage gamma delta (gd) T cells to target and kill cancer cells. Its platform offers off-the-shelf, tumor-specific therapies with potential for durable responses and fewer toxicities. The company focuses on hematologic malignancies and solid tumors, leveraging strategic partnerships and proprietary technology to advance targeted, immune-activating cancer treatments.
This description was generated via AI from an annual report. Updated about 1 year ago.